ESTRO 2024 - Abstract Book

S1319

Clinical - Head & neck

ESTRO 2024

[49] Ricchetti F, Wu B, McNutt T, Wong J, Forastiere A, Marur S, et al. Volumetric change of selected organs at risk during IMRT for oropharyngeal cancer. Int J Radiat Oncol Biol Phys 2011;80:161 – 8. https://doi.org/10.1016/j.ijrobp.2010.01.071.

[50] Chetty IJ, Rosu-Bubulac M. Deformable Registration for Dose Accumulation. Seminars in Radiation Oncology 2019;29:198 – 208. https://doi.org/10.1016/j.semradonc.2019.02.002.

[51] Schultheiss TE, Tomé WA, Orton CG. It is not appropriate to “deform” dose along with deformable image registration in adaptive radiotherapy: Point/Counterpoint. Med Phys 2012;39:6531 – 3. https://doi.org/10.1118/1.4722968. [52] Zhong H, Adams J, Glide-Hurst C, Zhang H, Li H, Chetty I. Development of a deformable dosimetric phantom to verify dose accumulation algorithms for adaptive radiotherapy. J Med Phys 2016;41:106. https://doi.org/10.4103/0971-6203.181641. [53] Servagi-Vernat S, Ali D, Roubieu C, Durdux C, Laccourreye O, Giraud P. Dysphagia after radiotherapy: State of the art and prevention. European Annals of Otorhinolaryngology, Head and Neck Diseases 2015;132:25 – 9. https://doi.org/10.1016/j.anorl.2013.09.006.

1660

Digital Poster

Quality of life in patients undergoing personalised follow-up in head and neck cancer

Laura Dean, Teresa Guerrero Urbano, Catherine Oakley, Mary Lei

Guy's and St. Thomas' NHS Foundation Trust, Oncology, London, United Kingdom

Purpose/Objective:

A Personalised stratified Follow-Up (PFU) pathway for patients who have been treated for Head and Neck Cancer (HNC) was implemented within our institution in 2021. Suitable patients (disease free; no high-risk factors of disease recurrence, ≤G2 toxicities) are discharged by oncologists at their 2 -year or subsequent follow-up appointment, onto a PFU pathway. NHSE state that to ensure care delivery within PFU pathways is optimised, clinicians must determine quality of life (QOL) needs for its patients (NHSE, 2019). In order to optimise care provision, we wished to evaluate the QOL of patients within PFU in context of their tumour subsite, treatment modality and age.

Material/Methods:

Patients entering the PFU pathway were invited to complete a EORTC QLQ HN43 Patient Reported Outcome Measure (PROM) questionnaire. Questionnaires were sent electronically using the DrDoctor platform. Paper copies were available according to patient preference. Within the questionnaire, patients reported concerns using a 4 point Likert scale to indicate impact on QOL. These ‘raw’ response scores were converted to summary scores ranging from 0 to 100. Scores above 50 were pragmatically identified as of Significant Concern (SC) to patients.